CSS
ADCT icon

Cubist Systematic Strategies’s ADC Therapeutics ADCT Stock Holding History

Cubist Systematic Strategies’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-120,775
Closed -$542K – 2880
2024
Q1 		$542K Buy
+120,775
New +$445K ﹤0.01% 2564
2023
Q3 		– Sell
-27,437
Closed -$59K – 3274
2023
Q2 		$59K Buy
27,437
+2,391
+10% +$5.38K ﹤0.01% 3074
2023
Q1 		$48.8K Sell
25,046
-1,590
-6% -$5.87K ﹤0.01% 3565
2022
Q4 		$102K Buy
26,636
+15,117
+131% +$60.5K ﹤0.01% 3799
2022
Q3 		$56K Buy
+11,519
New +$83.4K ﹤0.01% 4111
2021
Q4 		– Sell
-9,256
Closed -$251K – 3439
2021
Q3 		$251K Sell
9,256
-6,996
-43% -$179K ﹤0.01% 2457
2021
Q2 		$396K Buy
+16,252
New +$377K ﹤0.01% 2159

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cubist Systematic Strategies's ADCT Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of ADC Therapeutics (ADCT) in Q2 2024, closing a stake of 120,775 shares — an estimated $542K sold.

Cubist Systematic Strategies first reported a position in ADCT in Q2 2021 and held it in 7 quarters. The position peaked at $542K in Q1 2024. 74 funds tracked by Wall St. Rank hold ADCT as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining ADC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 120,775 ADC Therapeutics shares in Q2 2024, an estimated $542K.
  • Cubist Systematic Strategies first reported a position in ADC Therapeutics in Q2 2021 and held it in 7 quarters.
  • Cubist Systematic Strategies's ADC Therapeutics position peaked at $542K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.